Impact of HLA-B*52:01-Driven Escape Mutations on Viral Replicative Capacity.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
16 06 2020
Historique:
received: 27 01 2020
accepted: 10 04 2020
pubmed: 24 4 2020
medline: 18 12 2020
entrez: 24 4 2020
Statut: epublish

Résumé

HLA-B*52:01 is strongly associated with protection against HIV disease progression. However, the mechanisms of HLA-B*52:01-mediated immune control have not been well studied. We here describe a cohort with a majority of HIV C-clade-infected individuals from Delhi, India, where HLA-B*52:01 is highly prevalent (phenotypic frequency, 22.5%). Consistent with studies of other cohorts, expression of HLA-B*52:01 was associated with high absolute CD4 counts and therefore a lack of HIV disease progression. We here examined the impact of HLA-B*52:01-associated viral polymorphisms within the immunodominant C clade Gag epitope RMTSPVSI (here, RI8; Gag residues 275 to 282) on viral replicative capacity (VRC) since HLA-mediated reduction in VRC is a central mechanism implicated in HLA-associated control of HIV. We observed in HLA-B*52:01-positive individuals a higher frequency of V280T, V280S, and V280A variants within RI8 (

Identifiants

pubmed: 32321820
pii: JVI.02025-19
doi: 10.1128/JVI.02025-19
pmc: PMC7307159
pii:
doi:

Substances chimiques

Epitopes, T-Lymphocyte 0
HIV Core Protein p24 0
HLA-B*52:01 antigen 0
HLA-B52 Antigen 0
Immunodominant Epitopes 0
gag Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI133673
Pays : United States
Organisme : Wellcome Trust
ID : WT104748MA
Pays : United Kingdom

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

Front Immunol. 2016 Jan 18;6:665
pubmed: 26834742
J Exp Med. 2004 Apr 5;199(7):905-15
pubmed: 15067030
Infect Genet Evol. 2006 Nov;6(6):436-9
pubmed: 16563877
J Virol. 2007 Nov;81(22):12608-18
pubmed: 17728232
Immunity. 2012 Sep 21;37(3):426-40
pubmed: 22999948
Genet Mol Res. 2012 Feb 03;11(1):221-8
pubmed: 22370889
J Virol. 2013 Feb;87(4):2253-63
pubmed: 23236061
Sci Rep. 2016 Sep 19;6:32251
pubmed: 27642070
J Virol. 2012 Oct;86(19):10870-2
pubmed: 22811530
Science. 2013 Apr 5;340(6128):87-91
pubmed: 23559252
Genes Immun. 2014 Apr;15(4):256-62
pubmed: 24718028
J Virol. 2007 Aug;81(15):8346-51
pubmed: 17507468
Nat Med. 2016 Jun;22(6):606-13
pubmed: 27183217
Nature. 2009 Apr 2;458(7238):641-5
pubmed: 19242411
Retrovirology. 2016 Sep 08;13(1):65
pubmed: 27608713
J Virol. 2008 Sep;82(18):9216-27
pubmed: 18614631
Annu Rev Med. 2012;63:131-45
pubmed: 22248321
J Virol. 2019 Mar 21;93(7):
pubmed: 30674626
J Virol. 2009 Mar;83(6):2743-55
pubmed: 19116253
J Infect Dis. 2017 Dec 12;216(11):1415-1424
pubmed: 28968792
J Immunol. 2011 May 15;186(10):5675-86
pubmed: 21498667
AIDS. 2014 Jul 17;28(11):1687-90
pubmed: 24853499
J Virol. 2018 Feb 12;92(5):
pubmed: 29237835
Nature. 2004 Dec 9;432(7018):769-75
pubmed: 15592417
J Virol. 2005 Sep;79(17):11529-32
pubmed: 16103206
Retrovirology. 2015 Nov 19;12:98
pubmed: 26585907
J Virol. 2012 Dec;86(24):13202-16
pubmed: 23055555
Nat Med. 2004 Mar;10(3):282-9
pubmed: 14770175
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
Indian J Virol. 2010 Jun;21(1):3-7
pubmed: 23637473
J Virol. 2015 May;89(10):5330-9
pubmed: 25741000
Int J Rheum Dis. 2014 Mar;17(3):238-47
pubmed: 24548718
J Virol. 2014 Nov;88(22):12937-48
pubmed: 25165115
J Virol. 2010 Oct;84(20):10820-31
pubmed: 20702636
Dis Colon Rectum. 2003 Oct;46(10 Suppl):S10-4
pubmed: 14530653
J Virol. 1999 Dec;73(12):10191-8
pubmed: 10559335
PLoS Pathog. 2012;8(11):e1003041
pubmed: 23209412
Cell Rep. 2016 Nov 22;17(9):2210-2220
pubmed: 27880898
Immunol Lett. 2004 May 15;93(2-3):211-5
pubmed: 15158619
J Virol. 2012 Mar;86(6):3193-9
pubmed: 22238317
Hum Immunol. 2007 May;68(5):392-417
pubmed: 17462507
J Virol. 2005 Jul;79(13):8171-81
pubmed: 15956562
Arthritis Rheumatol. 2015 May;67(8):2226-32
pubmed: 25931203
Clin Exp Immunol. 1992 Jan;87(1):20-3
pubmed: 1733633
Nat Med. 2004 Mar;10(3):275-81
pubmed: 14966520
Antiviral Res. 2011 Dec;92(3):479-83
pubmed: 22027647
Tissue Antigens. 2002 Oct;60(4):309-18
pubmed: 12472660
Microbes Infect. 2013 Nov;15(13):874-86
pubmed: 23968885
Clin Rheumatol. 2017 Jan;36(1):173-181
pubmed: 27815653
Genet Mol Res. 2015 Nov 23;14(4):14929-35
pubmed: 26600554
J Virol. 2006 Apr;80(7):3617-23
pubmed: 16537629
J Virol. 2014 May;88(9):4764-75
pubmed: 24522911
J Virol. 2007 Feb;81(4):2031-8
pubmed: 17108020
N Engl J Med. 2001 May 31;344(22):1668-75
pubmed: 11386265
PLoS Pathog. 2015 Jun 15;11(6):e1004954
pubmed: 26076345
J Immunol. 1995 Apr 15;154(8):4174-86
pubmed: 7535824
Nat Genet. 2007 Jun;39(6):733-40
pubmed: 17496894
J Exp Med. 2008 May 12;205(5):1009-17
pubmed: 18426987
AIDS. 2013 Jul 17;27(11):1707-16
pubmed: 23462218

Auteurs

Ming-Han Chloe Tsai (MC)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom chloe.tsai@crick.ac.uk.

Supriya Singh (S)

Department of Biotechnology, National Centre for Disease Control, Delhi, India.

Emily Adland (E)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Philip Goulder (P)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH